<DOC>
	<DOCNO>NCT00796861</DOCNO>
	<brief_summary>The study see whether treatment Sunitinib decrease accumulation ascites patient refractory malignant ascites .</brief_summary>
	<brief_title>Trial Sunitinib Refractory Malignant Ascites</brief_title>
	<detailed_description>This single arm , non-randomized , phase II pilot study patient stop cytotoxic biologic therapy neoplasm suffer malignant ascites require drainage comfort . The study employ Simon 2-stage optimal design . Initially 17 patient would enrol . If response among first 12 patient , study would terminate . Otherwise trial would expand 23 total 37 patient . If 3 few response end trial , investigation would warrant .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Solid tumor malignancy failure least one biologic cytotoxic regimen , inability receive standard treatment due performance status ( PS &gt; 2 ) . Ascites base paracentesis CT scan within one month prior enrollment Life expectancy &gt; 3 month Indwelling paracentesis catheter permit , paracentesis permit investigator discretion Negative urine pregnancy test females All subject must agree use birth control All subject must abstain eat grapefruit grapefruit juice . They must tell physician change medication include overthecounter herbal supplement . History congestive heart failure Creatinine &gt; 2.0 Pregnant nursing ALT &gt; 2.5 time upper limit normal Blood pressure &gt; 160/90 ( antihypertensive permit ) Gastrointestinal intraabdominal hemorrhage within last 6 month History QTc &gt; 450 millisecond Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>malignant ascites</keyword>
</DOC>